Symetis, a Ecublens, Switzerland-based medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions, has agreed to be acquired by Boston Scientific (NYSE: BSX), for $435m.

Polyphor Ltd., an Allschwil, Switzerland-based clinical stage specialty pharma company focused on the development of macrocycle drugs addressing antibiotic resistance and respiratory diseases, completed a CHF 40m funding round.